The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online 20 February 2001.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vang, T.
Right arrow Articles by Taskén, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vang, T.
Right arrow Articles by Taskén, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0022-1007/2001/2/497/ $5.00
The Journal of Experimental Medicine, Volume 193, Number 4, February 19, 2001 497-508

Original Article

Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor

Torkel Vanga, Knut Martin Torgersena, Vibeke Sundvoldb, Manju Saxenac, Finn Olav Levya, Bjørn S. Skålhegga, Vidar Hanssona, Tomas Mustelinc,d, and Kjetil Taskéna
a Department of Medical Biochemistry, Institute of Basic Medical Sciences, University of Oslo, N-0317 Oslo, Norway
b Institute of Immunology, University of Oslo, The National Hospital, N-0027 Oslo, Norway
c La Jolla Institute for Allergy and Immunology, San Diego, California 92121
d La Jolla Cancer Research Center, The Burnham Institute, La Jolla, California 92037

Correspondence to: Tomas Mustelin, La Jolla Cancer Center, The Burnham Institute, 70901 North Torrey Pines Rd., La Jolla, CA 92037. Tel:858-713-6270 Fax:858-713-6274 E-mail:tmustelin{at}burnham-inst.org.

In T cells, cAMP-dependent protein kinase (PKA) type I colocalizes with the T cell receptor–CD3 complex (TCR/CD3) and inhibits T cell function via a previously unknown proximal target. Here we examine the mechanism for this PKA-mediated immunomodulation. cAMP treatment of Jurkat and normal T cells reduces Lck-mediated tyrosine phosphorylation of the TCR/CD3 {zeta} chain after T cell activation, and decreases Lck activity. Phosphorylation of residue Y505 in Lck by COOH-terminal Src kinase (Csk), which negatively regulates Lck, is essential for the inhibitory effect of cAMP on {zeta} chain phosphorylation. PKA phosphorylates Csk at S364 in vitro and in vivo leading to a two- to fourfold increase in Csk activity that is necessary for cAMP-mediated inhibition of TCR-induced interleukin 2 secretion. Both PKA type I and Csk are targeted to lipid rafts where proximal T cell activation occurs, and phosphorylation of raft-associated Lck by Csk is increased in cells treated with forskolin. We propose a mechanism whereby PKA through activation of Csk intersects signaling by Src kinases and inhibits T cell activation.

Key Words: protein kinase A, Csk, T cell activation, tyrosine phosphorylation, immunomodulation


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS